Tigermed (03347) has announced its intention to repurchase A-shares using its own funds or raised capital through methods such as centralized bidding or other legally permitted means. This move aims to support the company's healthy, stable, and long-term growth, bolster investor confidence, protect the interests of shareholders, and further establish a sustainable incentive mechanism. The repurchase is based on the company's confidence in its development prospects and intrinsic value. The repurchased shares are intended for future implementation of A-share equity incentive plans or A-share employee stock ownership plans, as well as for reducing the company's registered capital. The total amount for the share repurchase will be no less than 5 billion yuan and no more than 10 billion yuan, with a repurchase price not exceeding 60.00 yuan per share (including 60.00 yuan). For employee stock ownership plans or equity incentives, the number of shares will not exceed 60% of the total repurchase amount, while the shares to be canceled to reduce registered capital will account for no less than 40% of the total repurchase.